The global scale of hepatitis B infection is well known but its impact is still being understood.
Missed hepatitis B infection impacts lymphoma therapy especially increased risk of hepatitis …

Nearly a billion people worldwide are infected with the hepatitis B Virus (HBV) and about a
third of them have chronic infection. HBV is an important cause of morbidity and mortality …

Hepatitis B reactivation is a common complication in lymphoma patients under
immunosuppressive treatment with potentially serious and life-threating consequences. In …

Reactivation of hepatitis B virus (HBV) is a known complication that occurs in patients
receiving chemotherapy especially for malignant lymphoma. The increased risk in …

Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-
Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or …

Introduction: In patients with lymphoma the detection of positive hepatitis B or C viruses
(HBV and HCV) serology involves crucial therapeutic consequences. In HBV-infected …

Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world
despite available prophylactic vaccines. Non-Hodgkin's lymphoma is the most common …

Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and
mortality, is a common and well-known complication that occurs during the treatment of non …

Background In surface antigen of hepatitis B virus (HBsAg)-positive carrier for anticancer
treatment of malignant lymphoma, it is well recognized that reactivation of hepatitis B virus …

Purpose Hepatitis B virus (HBV) reactivation is a potentially fatal complication of
chemotherapy that can be largely prevented with antiviral prophylaxis. It remains unclear …